| 引用本文:孟慧1,2，孙旭2，念家云1,2，于明薇2，王笑民2.斑蝥酸钠联合化疗治疗进展期胃癌的Meta分析[J].世界中医药,2017,(10):. |
|
| 斑蝥酸钠联合化疗治疗进展期胃癌的Meta分析 |
| Sodium Cantharidate Combined with Chemotherapy in Advanced Gastric Cancer:A Meta-analysis |
| 投稿时间：2016-09-26 |
| DOI：10.3969/j.issn.1673-7202.2017.10.055 |
| 中文关键词: 斑蝥酸钠 化疗 进展期胃癌 随机对照试验 Meta分析 |
| English Keywords:Sodium cantharidate Chemotherapy Advanced grastric cancer Randomized controlled trail Meta-analysis |
| 基金项目:北京市科技计划项目(D161100005116005）；北京市医院管理局临床技术创新项目(XMLX201410） |
|
| 摘要点击次数: 1151 |
| 全文下载次数: 755 |
| 中文摘要: |
| 目的：系统评价斑蝥酸钠联合化疗治疗进展期胃癌的有效性和安全性。方法：计算机检索MEDLINE、Pubmed、Cochrane图书馆、中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)、维普中文科技期刊全文数据库（VIP）、万方数据库(WanFang),检索时间为各数据库建库至2016年9月，纳入斑蝥酸钠联合化疗治疗进展期胃癌的随机对照试验。按照Cochrane协作网的标准对纳入文献进行方法学质量评价，提取相关数据信息，RevMan5.3软件进行数据分析。结果：共纳入研究7项，450例患者，观察组231例，对照组219例。Meta分析显示，斑蝥酸钠可改善患者生命质量［RR=2.14，95%CI(1.55，2.96)，P<0.00001］，减轻骨髓抑制［RR=0.69，95%CI(0.59，0.81)，P<0.00001］，减轻恶心呕吐等消化道不良反应［RR=0.61，95%CI(0.52，0.72)，P<0.00001］。但对于提高进展期胃癌患者的近期有效率无明显优势［RR=1.29，95%CI(0.99，1.66)，P=0.06］。结论：目前研究表明斑蝥酸钠联合化疗可提高进展期胃癌患者的生命质量、减轻骨髓毒性、减轻恶心呕吐等不良反应。今后需开展更多高质量、大样本研究，为循证医学提供更可靠的证据。 |
| English Summary: |
| To evaluate the efficacy and safety of sodium cantharidate combined with chemotherapy in the treatment of advanced gastric cancer. Methods:MEDLINE, Pubmed, Cochrane library retrieval, Chinese biomedical literature database (CBM), Chinese Journal Full-text Database (CNKI), VIP Chinese PSTP (VIP) and Wanfang database (WanFang) were searched from their inception to September 2016 by computer, and the randomized controlled trails(RCTs) about sodium cantharidinate combined with chemotherapy for advanced gastric cancer were included. The methodological quality of the included studies were evaluated according to the criteria of Cochrane Handbook for Systematic Reviews of interventions, then the relevant data extracted, and RevMan5.3 software was used for data analysis. Results:Seven studies involving 450 participants were included, among which 231 participants took part in sodium cantharidate plus chemotherapy and 219 chemotherapy. The results of meta-analysis showed that sodium cantharidinate could improve the quality of life［RR=2.14，95%CI(1.55，2.96), P<0.00001］, and decrease bone marrow suppression［RR=0.69，95%CI(0.59，0.81), P<0.00001］ and gastrointestinal side-effects［RR=0.61，95%CI(0.52，0.72), P<0.00001］.But had little advantage in improving patients' recent effective rate.Conclusion:Recent studies suggest that treating the advanced grastric cancer with sodium cantharidinate could improve the quality of life, decrease bone marrow suppression and gastrointestinal side-effects. More hige quality and large sample studies are needed in the future to provide more reliable evidence for evidence-based medicine(EBM). |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
